Compare PRT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRT | VERU |
|---|---|---|
| Founded | 2017 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 40.9M |
| IPO Year | N/A | 1996 |
| Metric | PRT | VERU |
|---|---|---|
| Price | $2.76 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | ★ 68.6K | 51.7K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | ★ 13.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.61 | $0.36 |
| 52 Week High | $4.28 | $4.59 |
| Indicator | PRT | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 39.49 |
| Support Level | $2.75 | $2.13 |
| Resistance Level | $4.03 | $2.70 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 3.45 | 3.70 |
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.